Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data

Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data Tue, 3 Aug 2004 A hearing about the possible connection between suicide and antidepressant drugs will be held on Aug 4, by the California Senate by Sen. Tom Torkalson, chairman of the Senate Task Force on Youth and Workplace Wellness…

Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options

Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options Tue, 16 Aug 2005 A series of current articles in The Wall Street Journal, the Journal of the American Medical Association (JAMA), and the New York Times describe the many questionable non-medical income-producing activities that America¹s physicians…

FDA Suspends ADHD Drug Safety Study-Approves Risperdal for Autistic Children Without Public Hearing

Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.

“Some of the children were prescribed anti-psychotics, rather than discontinued from ADHD therapy.”

"That thing I’m worried about…where the MedGuide would help, where it might even warrant a black box, if this is common, where somebody hallucinates and then gets put on an anti-psychotic drug. That would really be something worth making sure it doesn’t happen,"

National Class Action Filed against Drug-maker for Paxil-induced Suicides in Youths

Below a press release from the lawfirm, Baum Hedlund, announces it has filed a class action lawsuit against GlaxoSmithKline  charging the company with fraud, negligence, strict liability, and breach of warranty in its marketing of Paxil (Seroxat) by concealing the risk of suicide.